Alberta Hoi
Monash University
H-index: 28
Oceania-Australia
Top articles of Alberta Hoi
Smith-specific regulatory T cells halt the progression of lupus nephritis
Nature Communications
2024/2/6
SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus—an analysis of anti-double-stranded DNA monitoring
Rheumatology
2024/2/1
Autoimmune Rheumatic Diseases in Australian Aboriginal and Torres Strait Islander Peoples: What Do We Know?
2024/1/14
Enrolment of the first paediatric cohort into the Australian lupus registry and biobank: A single-centre experience
Lupus
2024/4/8
Alberta Hoi
H-Index: 19
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation
2024/4/1
OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set
Seminars in arthritis and rheumatism
2024/4/1
P54 Screening for primary aldosteronism in hypertensive patients with systemic lupus erythematosus: are we doing it enough?
2024/3/1
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a …
Annals of the Rheumatic Diseases
2024/2/29
LO-004 Frequency and determinants of flare and persistently active disease in a large multinational prospective lupus cohort
2023/7/1
POS1481 INFORMING TRIAL MEASUREMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: FREQUENCY OF DOMAIN-SPECIFIC DISEASE ACTIVITY IN A MULTI-NATIONAL OBSERVATIONAL COHORT
2023/6/1
Primary aldosteronism: an unsuspected culprit of hypertension in systemic lupus erythematosus?
2023/11/1
The use of belimumab in three cases of refractory lupus nephritis
Internal Medicine Journal
2023/10
Alberta Hoi
H-Index: 19
OP0048 RISK OF FLARE AND DAMAGE ACCRUAL AFTER TAPERING GLUCOCORTICOIDS IN SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
2023/6/1
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus …
The Lancet Rheumatology
2023/10/1
OP0226 ATTAINMENT OF LUPUS LOW DISEASE ACTIVITY STATE EXCLUSIVE OF REMISSION IS PROTECTIVE AGAINST ADVERSE OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS
2023/6/1
Patterns and prevalence of cognitive dysfunction in systemic lupus erythematosus
Journal of the International Neuropsychological Society
2023/6
Cluster analysis and subphenotype stratification in lupus erythematosus based on data from the Asia Pacific Lupus Collaboration cohort (APLC-CASTLE)
LUPUS & KCR 2023 [15th International Congress on Systemic Lupus Erythematosus](17/05/2023-20/05/2023, Seoul)
2023/8/6
Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study
Arthritis & Rheumatology
2023/3
CSL362 potently and specifically depletes pDCs in vitro and ablates SLE-immune complex-induced IFN responses
Iscience
2023/7/21
Clinical associations of cognitive dysfunction in systemic lupus erythematosus
Lupus Science & Medicine
2023/2/1
Yifat Glikmann-Johnston
H-Index: 8
Alberta Hoi
H-Index: 19